Qigenix (“key-gen’-ix”) is a privately held clinical stage medical device company founded by Dr. Todd Ovokaitys in Carlsbad, California. The Qigenix lead product is the QiLaser, which is designed to increase homing and integration of stem cells. The QiLaser is effective with many different types of stem cells and, as a low power laser using advanced holographic signals, it can penetrate 6-8 centimeters into the human body, providing critical messaging for stem cells destined for major organs.

The first disease within the regenerative market that Qigenix will focus on is heart failure. Nearly 6 million Americans are currently living with Congestive Heart Failure (CHF). Approximately 550,000 new cases are diagnosed in the U.S. each year.

Congestive Heart Failure affects people of all ages, from children and young adults to the middle-aged and the elderly. Almost 1.4 million persons with CHF are under 60 years of age. Heart failure is responsible for 11 million physician visits each year, and more hospitalizations than all forms of cancer combined. The first clinical study of CHF with the QiLaser is being conducted in Armenia using stem cells from cord blood infused through an IV.